Analyst Ratings for [REGN] Regeneron Pharmaceuticals, Inc.

2/5/25	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma Leerink Partners
$762 $834
1/16/25	Downgrades	Buy Neutral	X
REGN Regeneron Pharma UBS
$1130 $738
12/10/24	Resumed	Underperform	X
REGN Regeneron Pharma BofA Securities
$565
11/15/24	Initiated	Outperform	X
REGN Regeneron Pharma Wolfe Research
$1150
11/14/24	Initiated	Neutral	X
REGN Regeneron Pharma Citigroup
$895
9/24/24	Downgrades	Outperform Mkt Perform	X
REGN Regeneron Pharma Leerink Partners
$1175 $1077
3/12/24	Initiated	Outperform	X
REGN Regeneron Pharma Bernstein
$1125
1/12/24	Upgrades	Sec Perform Outperform	X
REGN Regeneron Pharma RBC Capital Mkts
$884 $1076
11/9/23	Initiated	Hold	X
REGN Regeneron Pharma Deutsche Bank
$800
11/3/23	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma Raymond James
$950
8/21/23	Upgrades	Hold Buy	X
REGN Regeneron Pharma Canaccord Genuity
$720 $992
8/21/23	Reiterated	Perform	X
REGN Regeneron Pharma Oppenheimer
$950 $1050
6/28/23	Downgrades	Buy Hold	X
REGN Regeneron Pharma Canaccord Genuity
$953 $720
3/27/23	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma SVB Securities
$834 $976
3/24/23	Upgrades	Hold Buy	X
REGN Regeneron Pharma Jefferies
$675 $925
3/23/23	Upgrades	Underperform Mkt Perform	X
REGN Regeneron Pharma Raymond James
1/30/23	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma Cowen
$775 $875
1/20/23	Upgrades	Neutral Overweight	X
REGN Regeneron Pharma JP Morgan
$850
10/26/22	Downgrades	Mkt Perform Underperform	X
REGN Regeneron Pharma Raymond James
10/17/22	Downgrades	Outperform In-line	X
REGN Regeneron Pharma Evercore ISI
$760
9/9/22	Upgrades	Underperform Hold	X
REGN Regeneron Pharma Jefferies
$536 $675
9/9/22	Upgrades	Eq-Weight Overweight	X
REGN Regeneron Pharma Morgan Stanley
$625 $851
7/25/22	Downgrades	Outperform Mkt Perform	X
REGN Regeneron Pharma SVB Leerink
$630
7/13/22	Initiated	Neutral	X
REGN Regeneron Pharma Cantor Fitzgerald
$625
6/6/22	Initiated	Underperform	X
REGN Regeneron Pharma Jefferies
$536
5/23/22	Initiated	Outperform	X
REGN Regeneron Pharma SVB Leerink
$738
1/5/22	Downgrades	Neutral Underperform	X
REGN Regeneron Pharma BofA Securities
$675 $575
1/3/22	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma Bernstein
$660
12/15/21	Downgrades	Outperform Mkt Perform	X
REGN Regeneron Pharma Bernstein
$660
12/9/21	Resumed	Overweight	X
REGN Regeneron Pharma Wells Fargo
$750
12/7/21	Resumed	Market Perform	X
REGN Regeneron Pharma Cowen
$625
11/19/21	Resumed	Outperform	X
REGN Regeneron Pharma BMO Capital Markets
$780
11/5/21	Downgrades	Buy Hold	X
REGN Regeneron Pharma The Benchmark Company
6/29/21	Initiated	Buy	X
REGN Regeneron Pharma H.C. Wainwright
$703
1/25/21	Upgrades	Mkt Perform Outperform	X
REGN Regeneron Pharma BMO Capital Markets
$630
1/13/21	Upgrades	Hold Buy	X
REGN Regeneron Pharma The Benchmark Company
$590
1/8/21	Upgrades	Neutral Buy	X
REGN Regeneron Pharma Citigroup
$635 $575
8/7/19	Upgrades	Neutral Outperform	X
REGN Regeneron Pharma Robert W. Baird
$410
6/18/19	Downgrades	Buy Hold	X
REGN Regeneron Pharma Argus
5/23/19	Resumed	Neutral	X
REGN Regeneron Pharma Citigroup
5/21/19	Initiated	Neutral	X
REGN Regeneron Pharma Credit Suisse
$336
5/8/19	Reiterated	Hold	X
REGN Regeneron Pharma Canaccord Genuity
$408 $353
1/4/19	Upgrades	Neutral Buy	X
REGN Regeneron Pharma Guggenheim
10/1/18	Initiated	Neutral	X
REGN Regeneron Pharma Cantor Fitzgerald
$415
5/4/18	Reiterated	Hold	X
REGN Regeneron Pharma Canaccord Genuity
$356 $304
4/9/18	Downgrades	Outperform Mkt Perform	X
REGN Regeneron Pharma Raymond James
2/21/18	Downgrades	Buy Hold	X
REGN Regeneron Pharma Canaccord Genuity
$522 $356

REGN Regeneron Pharmaceuticals, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.